- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Eganelisib (IPI-549) 是PI3K-γ的有效抑制劑,選擇性是對其他脂質(zhì)和蛋白激酶的100倍以上。生化IC50為16 nM。
Eganelisib (IPI-549) Chemical Structure
CAS: 1693758-51-8
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
RAW264.7 | Function assay | 30 mins | Inhibition of PI3Kgamma in C5a-stimulated mouse RAW264.7 cells assessed as reduction in AKT phosphorylation at S473 incubated for 30 mins followed by stimulation with C5a for 3 mins by ELISA, IC50 = 0.0012 μM. | 27660692 | |
Sf9 | Function assay | 15 mins | Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay, IC50 = 0.016 μM. | 27660692 | |
Raji | Function assay | 30 mins | Inhibition of PI3Kdelta in IgM-stimulated human Raji cells assessed as reduction in AKT phosphorylation at S473 incubated for 30 mins followed by stimulation with IgM for 30 mins by ELISA, IC50 = 0.18 μM. | 27660692 | |
786-O | Function assay | 30 mins | Inhibition of PI3Kbeta in human 786-O cells assessed as reduction in AKT phosphorylation at S473 after 30 mins by ELISA, IC50 = 0.24 μM. | 27660692 | |
SKOV-3 | Function assay | 30 mins | Inhibition of PI3Kalpha in human SKOV-3 cells assessed as reduction in AKT phosphorylation at S473 after 30 mins by ELISA, IC50 = 0.25 μM. | 27660692 | |
Sf9 | Function assay | 15 mins | Inhibition of human recombinant full length N-terminal His6-tagged PI3K p110alpha/p85alpha coexpressed in baculovirus infected Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo, IC50 = 3.2 μM. | 27660692 | |
Sf9 | Function assay | 15 mins | Inhibition of human recombinant full length N-terminal His6-tagged PI3K p110beta/p85alpha coexpressed in baculovirus infected Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo , IC50 = 3.5 μM. | 27660692 | |
Sf9 | Function assay | Binding affinity to human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells by equilibrium fluorescence titration analysis, Kd = 0.00029 μM. | 27660692 | ||
Sf9 | Function assay | Binding affinity to human recombinant full length N-terminal His6-tagged PI3K p110alpha/p85alpha coexpressed in baculovirus infected Sf9 insect cells by equilibrium fluorescence titration analysis, Kd = 0.017 μM. | 27660692 | ||
Sf9 | Function assay | Binding affinity to human recombinant full length N-terminal GST-tagged PI3K p110delta/p85alpha coexpressed in baculovirus infected Sf9 insect cells by equilibrium fluorescence titration analysis, Kd = 0.023 μM. | 27660692 | ||
Sf9 | Function assay | Binding affinity to human recombinant full length N-terminal His6-tagged PI3K p110beta/p85alpha coexpressed in baculovirus infected Sf9 insect cells by equilibrium fluorescence titration analysis, Kd = 0.082 μM. | 27660692 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Eganelisib (IPI-549) 是PI3K-γ的有效抑制劑,選擇性是對其他脂質(zhì)和蛋白激酶的100倍以上。生化IC50為16 nM。 | ||
---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | IPI-549與PI3Kγ能夠緊密結(jié)合Kd值為290 pM,對其他I型PI3K亞型的親和力弱58倍以上。在對48種突變型和非突變型蛋白激酶和脂質(zhì)激酶的實驗中,濃度為1 μM的IPI-549對它們沒有顯著的抑制作用。在PI3K-α, -β, -γ和-δ依賴性的細胞內(nèi)p-AKT實驗中,IPI-549有效抑制PI3Kγ(IC50=1.2 nM),而對其他I類亞型具有146倍以上的選擇性。此外,IPI-549在體外抑制依賴于PI3Kγ骨髓來源細胞的遷移。在80種GPCRs、離子通道、和轉(zhuǎn)運體中,濃度為10 μM的IPI-549具有高選擇性。它具有中等的細胞透性,能夠透過Caco-2x單細胞層。在肝細胞中,代謝緩慢(t1/2 > 360 min)。對所檢測的CYP亞型(1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4)的IC50大于20μM[1]。 | |||
---|---|---|---|---|
細胞實驗 | 細胞系 | SKOV-3細胞 | ||
濃度 | -- | |||
孵育時間 | 30 min | |||
方法 | 將SKOV-3以200,000 cells/200 μL/well的密度接種于96孔細胞培養(yǎng)板中,培養(yǎng)于含10% FBS的RPMI-1640培養(yǎng)基中。在5% CO2、37℃培養(yǎng)箱中培養(yǎng)過夜。第二天,加入化合物,DMSO的終濃度為0.5%,在小分子化合物中孵育30分鐘(5% CO2,37℃)。然后加入預(yù)冷的Lysis buffer,將培養(yǎng)板置于冰上孵育5分鐘,3000 rpm,4℃離心5分鐘。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | p-AKT / AKT / p-p65 / p65 | 27642729 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | 在體內(nèi)模型中(小鼠、大鼠、犬類和猴子),IPI-549具有良好的口服生物利用度、低清除率、在組織中平均分布體積為1.2 L/kg。它在體內(nèi)具有良好的藥代動力學(xué)特征,能有效地、選擇性地抑制PI3Kγ。在小鼠模型中,口服IPI549能夠顯著地、劑量依賴性地減少中性粒細胞遷移。此外,在小鼠同源模型中,IPI-549通過改變腫瘤微環(huán)境中免疫細胞,可抑制腫瘤生長[1]。 | |
---|---|---|
動物實驗 | Animal Models | CD-1小鼠, Sprague-Dawley大鼠, 比格犬, 食蟹猴 |
Dosages | 0.5-1.25 mg/mL(For PO dosing); 5-10 mg/mL(for efficacy studies); 0.25-0.4 mg/mL(for IV dosing) | |
Administration | p.o.; i.v. |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT03980041 | Completed | Bladder Cancer|Urothelial Carcinoma|Solid Tumor|Advanced Cancer |
Infinity Pharmaceuticals Inc.|Bristol-Myers Squibb |
September 25 2019 | Phase 2 |
NCT02637531 | Unknown status | Advanced Solid Tumors (Part A/B/C/D)|Non-small Cell Lung Cancer (Part E)|Melanoma (Part E)|Squamous Cell Cancer of the Head and Neck (Part E)|Triple Negative Breast Cancer (Part F)|Adrenocortical Carcinoma (Part G)|Mesothelioma (Part G)|High-circulating Myeloid-derived Suppressor Cells (Part H) |
Infinity Pharmaceuticals Inc. |
December 2015 | Phase 1 |
分子量 | 528.56 | 分子式 | C30H24N8O2 |
CAS號 | 1693758-51-8 | SDF | Download Eganelisib (IPI-549) SDF |
Smiles | CC(C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 100 mg/mL ( (189.19 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : ?1 mg/mL Ethanol : ?1 mg/mL |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項